Qrons (QRON) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 24, 2026)


What is Qrons Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Qrons's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

QRON vs GBLX, ENDV, CNBX: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Qrons's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qrons Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qrons's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Qrons's Margin of Safety % (DCF FCF Based) falls into.


Qrons Business Description

Address 611 N. Brand Boulevard, Suite 1300, Glendale, CA, USA, 91203
Qrons Inc. is a biotechnology company, dedicated to developing biotech products, treatments, and technologies to combat neuronal and infectious diseases with a focus on antibiotic-resistant bacteria, which is becoming the prominent and rapidly growing world-wide cause of illness and death. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The company has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM for treating concussions and other diffused axonal injuries.